|Articles|October 2, 2003

ACT 2003 Winter Forum Conference Programme

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

BySharad Adekar, MD, PhD, CIP,Currien MacDonald

October 31st 2025

ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials

ByAndy Studna, Senior Editor

October 31st 2025

MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care

ByNancy Ghattas,Andy Studna, Senior Editor

October 31st 2025

ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward

ByAndy Studna, Senior Editor

October 30th 2025

Reducing Site Burden Through Better Technology Integration in Clinical Trials

ByRobin Douglas,Steve Rosenberg,Andy Studna, Senior Editor

October 30th 2025

ACT 2003 Winter Forum Conference Programme

Newsletter

Related Content

Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials

MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care

ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward

Reducing Site Burden Through Better Technology Integration in Clinical Trials

Trending on Applied Clinical Trials Online

Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines

ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials

MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care